In addition, the use of sodium-glucose cotransporter 2 (SGLT2) blockers seems to be a promising adjunct treatment option in patients with SARS-CoV2 infection and type 2 diabetes mellitus (T2DM) whereas an increased risk of protracted ketonemia and diabetic ketoacidosis was also reported [4]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.